Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Golan resident convicted of spying for Iran after passing tank movement, missile-impact data - 2Instructions to Redo Your Kona SUV for Improved Tasteful Allure and Usefulness
- 3From Amateur to Master: My Involvement in Photography
- 4Vote In favor of Your Favored Sort Of Dress
- 54 Home Rec center Hardware Decisions for Little Spaces
- Taste the World: Five Food sources That Have Dazzled Worldwide Palates
- Israel Police decry online defamation campaign against female officer in Jerusalem
- Army commander convicted of Guinea stadium massacre dies in prison
- Esteem Stuffed Gaming Workstations to Consider
- Lebanese Shi’a party Amal competing, coordinating with Hezbollah, experts tell ‘Post’
- New Year's Eve Live: Nashville's Big Bash: How to watch the star-studded country music special live
- FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- Lahav 433 head Asst.-Ch. Meni Benjamin named as police officer investigated for breach of trust
- A whale stranded at a Baltic Sea resort has swum off a sandbank. But it isn't safe yet
